Computational studies have begun to investigate a molecular basis of protein kinase function and the structural effects of activating mutations, which may ultimately control the activity signatures of cancer drugs and determine the scope of drug resistance mutations [59],[60]. The gene discussed is WEE1; the disease is cancer.